(Murcia : F. Hernández, 2009) Okamoto, Kinya; Neureiter, Daniel
Increasing insights into molecular alterations
of signalling pathways have led to the development of
specific targeted therapies for cancer. Due to the high
specificity of monoclonal antibodies or small molecule
inhibitors, identification of patients who will benefit
from these therapeutics is crucial for treatment success.
Furthermore, as classical endpoints of clinical trials are
not fully applicable to targeted therapies, biomarkers for
monitoring treatment response have to be identified.
The recent introduction of a multi-kinase inhibitor
for the treatment of liver cancer has accelerated efforts in
the field of biomarker research. As further novel targeted
therapies are on the horizon for liver cancer therapy, we
will here review candidate markers for new
hepatocellular carcinoma therapies, with a focus on
EGF- and VEGF-receptor related pathways.